

2023 Raleigh Campus Antibiogram Outpatient

GRAM POSITIVE									
Antibiogram 2023 Raleigh Campus Outpatient	* Anaerobic coverage	Enterococcus faecalis	Enterococcus faecium	Staphylococcus epidermidis	Staphylococcus haemolyticus	Staphylococcus lugdunensis	Staphylococcus saprophyticus	Staph aureus (MSSA)	Staph aureus (MRSA)
	Location	OUTPATIENTS							
# of isolates analyzed		976	46	414	47	61	268	574	379
		% Susceptible							
Ampicillin	*	100%	35%						
Ceftaroline								100%	100%
Clindamycin	*			73%	55%	89%	74%	75%	75%
Daptomycin								100%	99%
Erythromycin Base, Enteric	*			47%	30%			59%	14%
Gentamicin Synergy (high level)		87%	88%						
Levofloxacin		90%	37%						
Linezolid		98%	89%	100%	100%	100%	100%	100%	100%
Nitrofurantoin		100%	13%	99%	94%	100%	100%	100%	98%
Oxacillin				54%	47%	89%	47%	100%	0%
Penicillin G	*	99%	33%	0%	0%	0%	0%	0%	0%
Streptomycin Synergy (high level)		93%	67%						
Tetracycline/Doxycycline	*			79%	72%	98%	91%	92%	85%
Trimethoprim-sulfa				73%	83%	98%	98%	94%	88%
Vancomycin		98%	83%	100%	100%	100%	100%	100%	100%

This antibiogram has been prepared from SCC SOFT LIS.
 This antibiogram contains organisms isolated in 2022.
 Only the first isolate per patient is included in this data.
 * Denotes activity against anaerobes. Anaerobes are not tested for susceptibility profiles at WakeMed.

22 % of Outpatient MSSA are Clindmycin Inducible Resistant
 5% of Outpatient MRSA are Clindamycin Inducible Resistant

**Antibiograms are published annually for WakeMed Raleigh, WakeMed Cary and WakeMed North
 by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075**

**WakeMed Health and Hospitals
 Raleigh, NC**